Your present position: Home > Faculties Tel: +86-22-85682291             +86-22-85683031

Tian Hongqi, researcher and graduate student tutor, graduated from Department of Chemistry of Sichuan University in 1990 with a Bachelor Degree, graduated from Shanghai Institute of Organic Chemistry under Chinese Academy of Sciences in 1998 with a Doctoral Degree, engaging in post-doctoral research in Colorado State University during 1998-2001, working as a senior researcher in Array BioPharma during 2001-2009, hired as Principle Investigator (PI) in Tianjin International Joint Academy of Biomedicine after returning to China in 2009, and at the same time working as a part-time professor in both College of Pharmacy of Nankai University as well as College of Biotechnology of Tianjin University of Science and Technology, hired as a specially appointed researcher in National Key Laboratory of Drug Release Technology and Pharmacokinetics of Tianjin Drug Research Institute in 2012, hired as a researcher in Institute of Radiation Medicine under Chinese Academy of Medical Sciences in 2015, winner of “Thousands of People Plan” of Tianjin City in 2011 and hired as a specially invited expert at the same time, winner of Rewards for Excellent Overseas Personnel Initiated by Ministry of Human Resources and Social Security of the PRC in 2013, member of American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO), working as Member of Tianjin Binhai Anti-cancer Drug Development Industry Union and engaging in Major Anti-cancer Projects of Tianjin City, Sci-Tech Support Plan of Tianjin City, Innovation Fund of Tianjin City, Subsidy Projects for Excellent Scientific and Technological Activities of Overseas Personnel Initiated by Ministry of Human Resources and Social Security of the PRC as a responsible person, engaging in Major Science and Technology Projects of National New Drug Innovation as a sub-project responsible person; successively discovered 7 new compounds with potential drug value, including 5 compounds listed into pre-clinical research or Phase-I clinical research as new drug of Category 1.1, 1 compound becoming a brand new tool compound and 1 compound to enter pre-clinical research; 25 patent applications successively at home and abroad including 15 authorized patents, 17 articles published in internationally core journals; currently engaging in radioactive medicine as research field with detailed research directions as follows: design and synthesis of compounds of new type of isotope labeling as well as their biological mechanism researches on molecular imaging and cancer therapy; design and synthesis of new type of protein kinase inhibitors as well as their biological mechanism researches on cancer therapy; researches on synthesis methodology of new reaction as for important bioactive molecule.











Home | About us | Institutes | Newsroom | Sicence & Technology | Scientists | Resources | Join us
Tel: 022-85682291    Fax: 022-85683033    Add: No.238 baidi road, Nankai District, Tianjin, China
Tianjin ICP prepared No. 15006720-1